AU2003284231A1 - Treatment for reactive arthritis or bursitis - Google Patents
Treatment for reactive arthritis or bursitis Download PDFInfo
- Publication number
- AU2003284231A1 AU2003284231A1 AU2003284231A AU2003284231A AU2003284231A1 AU 2003284231 A1 AU2003284231 A1 AU 2003284231A1 AU 2003284231 A AU2003284231 A AU 2003284231A AU 2003284231 A AU2003284231 A AU 2003284231A AU 2003284231 A1 AU2003284231 A1 AU 2003284231A1
- Authority
- AU
- Australia
- Prior art keywords
- dosage unit
- dosage
- pharmaceutical formulation
- metronidazole
- bursitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010003267 Arthritis reactive Diseases 0.000 title claims description 27
- 208000002574 reactive arthritis Diseases 0.000 title claims description 27
- 206010006811 Bursitis Diseases 0.000 title claims description 26
- 238000011282 treatment Methods 0.000 title description 30
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 28
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 claims description 27
- 229960002421 minocycline hydrochloride Drugs 0.000 claims description 27
- 229960004150 aciclovir Drugs 0.000 claims description 26
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 26
- 229960000282 metronidazole Drugs 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- ZCDDBUOENGJMLV-QRPNPIFTSA-N Valacyclovir hydrochloride Chemical group Cl.N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 ZCDDBUOENGJMLV-QRPNPIFTSA-N 0.000 claims description 13
- 229940064636 valacyclovir hydrochloride Drugs 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 239000004098 Tetracycline Substances 0.000 claims description 6
- 229960002180 tetracycline Drugs 0.000 claims description 6
- 229930101283 tetracycline Natural products 0.000 claims description 6
- 235000019364 tetracycline Nutrition 0.000 claims description 6
- 150000003522 tetracyclines Chemical class 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000024891 symptom Diseases 0.000 description 12
- 210000001503 joint Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 7
- 210000003127 knee Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 241001260012 Bursa Species 0.000 description 3
- 206010063045 Effusion Diseases 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
- 241000607768 Shigella Species 0.000 description 3
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 210000003423 ankle Anatomy 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 206010030124 Oedema peripheral Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001361 achilles tendon Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 206010001986 Amoebic dysentery Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 208000002061 Cardiac Conduction System Disease Diseases 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 206010023201 Joint contracture Diseases 0.000 description 1
- 206010023215 Joint effusion Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- -1 L-valyl ester Chemical class 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 201000002064 aortic valve insufficiency Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000459 calcaneus Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000002089 crippling effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 210000000527 greater trochanter Anatomy 0.000 description 1
- 210000000474 heel Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical group O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229940108442 valtrex Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
- 229940107931 zovirax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2009238327A AU2009238327A1 (en) | 2002-10-15 | 2009-11-18 | Treatment for reactive arthritis or bursitis |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/271,117 | 2002-10-15 | ||
| US10/271,117 US6765000B2 (en) | 1999-03-17 | 2002-10-15 | Treatment for reactive arthritis or bursitis |
| PCT/US2003/032653 WO2004034987A2 (en) | 2002-10-15 | 2003-10-14 | Treatment for reactive arthritis or bursitis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009238327A Division AU2009238327A1 (en) | 2002-10-15 | 2009-11-18 | Treatment for reactive arthritis or bursitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003284231A1 true AU2003284231A1 (en) | 2004-05-04 |
Family
ID=32106409
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003284231A Abandoned AU2003284231A1 (en) | 2002-10-15 | 2003-10-14 | Treatment for reactive arthritis or bursitis |
| AU2009238327A Abandoned AU2009238327A1 (en) | 2002-10-15 | 2009-11-18 | Treatment for reactive arthritis or bursitis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009238327A Abandoned AU2009238327A1 (en) | 2002-10-15 | 2009-11-18 | Treatment for reactive arthritis or bursitis |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US6765000B2 (enExample) |
| EP (1) | EP1558266A4 (enExample) |
| JP (1) | JP2006503095A (enExample) |
| KR (1) | KR20050083762A (enExample) |
| CN (1) | CN100584335C (enExample) |
| AU (2) | AU2003284231A1 (enExample) |
| CA (1) | CA2502397A1 (enExample) |
| CH (1) | CH696629A5 (enExample) |
| MX (1) | MXPA05003930A (enExample) |
| WO (1) | WO2004034987A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7691831B2 (en) * | 1999-03-17 | 2010-04-06 | Ernest L. Bonner, Jr. | Pharmaceutical combination and method for treatment of reactive arthritis or bursitis |
| US20050137181A1 (en) * | 1999-03-17 | 2005-06-23 | Bonner Ernest L. | Method for treatment of reactive arthritis or bursitis |
| US6765000B2 (en) * | 1999-03-17 | 2004-07-20 | Bonner Jr Ernest L | Treatment for reactive arthritis or bursitis |
| US7884090B2 (en) * | 1999-03-17 | 2011-02-08 | Ernest L. Bonner, Jr. | Compositions and methods for the treatment of arthritis |
| CN1293883C (zh) * | 2004-05-21 | 2007-01-10 | 邹宏 | 一种美容修护液及其制备方法 |
| WO2005118525A1 (en) * | 2004-06-02 | 2005-12-15 | F.Hoffmann-La Roche Ag | Synthesis of amino-alkoxy-heptanoic alkyl ester |
| WO2006064516A1 (en) * | 2004-12-17 | 2006-06-22 | Venus Remedies Limited | Antibiotic combinations for providing total solution to the treatment of infections |
| WO2006096555A1 (en) * | 2005-03-04 | 2006-09-14 | Women And Infants Hospital Of Ri, Inc. | Compositions and methods for cancer treatment |
| CN102688492A (zh) * | 2007-03-23 | 2012-09-26 | 分子研究中心公司 | 包含四环素类的抗炎组合物及其用途 |
| CA2609104C (en) * | 2007-04-10 | 2017-09-05 | Exist Marketing Pty Ltd | Method and device for treating bursitis |
| EP2018864A1 (en) | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
| US20160045520A1 (en) * | 2014-08-18 | 2016-02-18 | Fabrizio De Silvestri | Use in one pill tablet capsule minocycline acycloguanosine atorvastatin and vitamin d3 in the treatment of rheumatoid arthritis |
| KR102806503B1 (ko) * | 2021-07-29 | 2025-05-16 | 가톨릭대학교 산학협력단 | 렘데시비르와 면역조절제 병용투여법을 통한 자가면역류마티스 질환 치료용 조성물 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2946801A (en) * | 1957-06-05 | 1960-07-26 | Standard Oil Co | Production of pyridine carboxylic acids |
| US3148212A (en) * | 1961-12-22 | 1964-09-08 | American Cyanamid Co | Reductive alkylation process |
| USRE26253E (en) * | 1963-05-17 | 1967-08-15 | And z-alkylamino-g-deoxytetracycline | |
| US4177796A (en) * | 1977-08-22 | 1979-12-11 | Franco Vila Jose J | Magnetic thermal vibrational device for the treatment of arthritis and the like |
| US4521411A (en) * | 1983-11-04 | 1985-06-04 | Theodora Koloff | Analgesic composition |
| US5728680A (en) * | 1987-12-30 | 1998-03-17 | Cytoven J.V. | Methods for normalizing numbers of lymphocytes |
| US5262173A (en) * | 1992-03-02 | 1993-11-16 | American Cyanamid Company | Pulsatile once-a-day delivery systems for minocycline |
| US5523297A (en) * | 1993-03-02 | 1996-06-04 | The Research Foundation Of State University Of New York | Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines |
| EP0693884A4 (en) * | 1993-04-16 | 1996-03-27 | Mccormick & Co Inc | ENCLOSURE COMPOSITIONS |
| GB9425487D0 (en) * | 1994-12-16 | 1995-02-15 | Res Inst | Osteoarthritis treatment |
| JPH09136842A (ja) * | 1995-11-14 | 1997-05-27 | Shigemasa Sawada | 抗慢性関節リウマチ剤 |
| US6093414A (en) * | 1997-08-11 | 2000-07-25 | Christopher C. Capelli | Silver-based antimicrobial compositions |
| US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| US5952367A (en) * | 1997-04-25 | 1999-09-14 | Pak; Kyoungsik | Method of treating pain cause by bursitis tendinitis arthritis |
| US6416779B1 (en) * | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
| US7303768B2 (en) * | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| US6326364B1 (en) * | 1999-02-08 | 2001-12-04 | Cedars-Sinai Medical Center | Use of 5-aminosalicylates as antimicrobial agents |
| US6087382A (en) * | 1999-03-17 | 2000-07-11 | Bonner, Jr.; Ernest L. | Method for treatment of reactive arthritis or bursitis |
| US6197776B1 (en) * | 1999-03-17 | 2001-03-06 | Ernest L. Bonner, Jr. | Method for treatment of reactive arthritis or bursitis |
| US7884090B2 (en) * | 1999-03-17 | 2011-02-08 | Ernest L. Bonner, Jr. | Compositions and methods for the treatment of arthritis |
| US6765000B2 (en) | 1999-03-17 | 2004-07-20 | Bonner Jr Ernest L | Treatment for reactive arthritis or bursitis |
| US20050137181A1 (en) * | 1999-03-17 | 2005-06-23 | Bonner Ernest L. | Method for treatment of reactive arthritis or bursitis |
| US7330856B2 (en) * | 2000-10-30 | 2008-02-12 | Tririga Llc | Item specification object management system |
| WO2002056832A2 (en) * | 2001-01-19 | 2002-07-25 | Newbiotics, Inc. | Methods to treat autoimmune and inflammatory conditions |
| US20040024624A1 (en) * | 2002-07-31 | 2004-02-05 | Ciscon Lawrence A. | Method and system for leveraging functional knowledge using a requirement and space planning tool in an engineering project |
-
2002
- 2002-10-15 US US10/271,117 patent/US6765000B2/en not_active Expired - Fee Related
-
2003
- 2003-10-14 WO PCT/US2003/032653 patent/WO2004034987A2/en not_active Ceased
- 2003-10-14 KR KR1020057006451A patent/KR20050083762A/ko not_active Ceased
- 2003-10-14 EP EP03776410A patent/EP1558266A4/en not_active Withdrawn
- 2003-10-14 MX MXPA05003930A patent/MXPA05003930A/es active IP Right Grant
- 2003-10-14 JP JP2004545314A patent/JP2006503095A/ja active Pending
- 2003-10-14 CN CN200380103653A patent/CN100584335C/zh not_active Expired - Fee Related
- 2003-10-14 AU AU2003284231A patent/AU2003284231A1/en not_active Abandoned
- 2003-10-14 CA CA002502397A patent/CA2502397A1/en not_active Abandoned
- 2003-10-14 CH CH00998/04A patent/CH696629A5/de not_active IP Right Cessation
-
2004
- 2004-07-20 US US10/896,612 patent/US7053073B2/en not_active Expired - Fee Related
-
2005
- 2005-02-04 US US11/051,171 patent/US20050176690A1/en not_active Abandoned
-
2009
- 2009-11-18 AU AU2009238327A patent/AU2009238327A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006503095A (ja) | 2006-01-26 |
| US7053073B2 (en) | 2006-05-30 |
| US20050176690A1 (en) | 2005-08-11 |
| US20030055022A1 (en) | 2003-03-20 |
| EP1558266A2 (en) | 2005-08-03 |
| CN1729006A (zh) | 2006-02-01 |
| KR20050083762A (ko) | 2005-08-26 |
| CN100584335C (zh) | 2010-01-27 |
| MXPA05003930A (es) | 2005-06-17 |
| CA2502397A1 (en) | 2004-04-29 |
| EP1558266A4 (en) | 2007-12-26 |
| CH696629A5 (de) | 2007-08-31 |
| US20050059640A1 (en) | 2005-03-17 |
| US6765000B2 (en) | 2004-07-20 |
| WO2004034987A3 (en) | 2004-07-15 |
| WO2004034987A2 (en) | 2004-04-29 |
| AU2009238327A1 (en) | 2009-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009238327A1 (en) | Treatment for reactive arthritis or bursitis | |
| US6465473B1 (en) | Method for treatment of reactive arthritis or bursitis | |
| US6197776B1 (en) | Method for treatment of reactive arthritis or bursitis | |
| Raborn et al. | Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study | |
| EP0980203B1 (en) | Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases | |
| AU2001280519A1 (en) | Method for treatment of reactive arthritis or bursitis | |
| US5883095A (en) | Formulations and methods to treat and prevent equine protozoal myeloencephalitis | |
| US20050137181A1 (en) | Method for treatment of reactive arthritis or bursitis | |
| US7691831B2 (en) | Pharmaceutical combination and method for treatment of reactive arthritis or bursitis | |
| CN111939179B (zh) | 眼镜蛇蛇毒或其提取物在制备降尿酸和/或抗痛风性关节炎的药物中的应用 | |
| Arie et al. | Crystal-associated rheumatic disease: Current management considerations | |
| JP2023553956A (ja) | 関節の炎症性障害のための併用療法 | |
| WO2025167710A1 (zh) | 三稠环化合物在制备预防和/或治疗炎性疾病药物中的应用 | |
| Powell, SJ & MacLeod | Ambilhar, a nitrothiazole derivative, in urinary tract bilharzia | |
| TABLETS | SILENCE FEAR. SILENCE INFECIlON. | |
| KR20060078344A (ko) | 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 헤르페스 감염 치료제 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |